SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.
Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
Upon joining, please ask to be joined into the Nephros conference call.
An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively, a replay of the call may be accessed until March 14th, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 3916556.
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit us at nephros.com.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
This email address is being protected from spambots. You need JavaScript enabled to view it.
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.95 |
Daily Change: | -0.09 -4.41 |
Daily Volume: | 22,418 |
Market Cap: | US$20.550M |
November 07, 2024 October 24, 2024 November 08, 2023 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load